This article is more than 5 years old. Information may no longer be current.

Novaliq GmbH appoints new CEO

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Novaliq GmbH has announced the appointment of Christian Roesky, PhD, as the company’s chief executive officer. The former CEO Bernhard Günther will take on the new role of chief innovation officer.

Roesky brings more than 15 years of eye care experience to Novaliq, having served many international pharmaceutical companies, including posts with Bausch + Lomb, Abbott and Novartis in Europe, according to a company press release.

“His experience and proven leadership will be highly beneficial as we move our many drug candidates through product development, clinical trials, approvals and commercialization,” Friedrich von Bohlen, PhD, chairman of the board for Novaliq, said of Roesky in the release.

Bohlen also recognized Günther “for his numerous contributions” to the company. “As the company’s co-founder, Bernhard has led Novaliq to develop a unique ocular therapeutics delivery technology, to raise capital and to hire a world class team that has resulted in the development of the current line of innovative products and the successful market launch of NovaTears, the first innovative EyeSol product,” he said.